|
1
|
Couse JF and Korach KS: Estrogen receptor
null mice: What have we learned and where will they lead us? Endocr
Rev. 20:358–417. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nilsson S, Mäkelä S, Treuter E, Tujague M,
Thomsen J, Andersson G, Enmark E, Pettersson K, Warner M and
Gustafsson JA: Mechanisms of estrogen action. Physiol Rev.
81:1535–1565. 2001.PubMed/NCBI
|
|
3
|
Pettersson K and Gustafsson J: Role of
estrogen receptor beta in estrogen action. Annu Rev Physiol.
63:165–192. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hall JM and McDonnell DP: The estrogen
receptor beta-isoform (ERbeta) of the human estrogen receptor
modulates ERalpha transcriptional activity and is a key regulator
of the cellular response to estrogens and antiestrogens.
Endocrinology. 140:5566–5578. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tsai MJ and O'Malley BW: Molecular
mechanisms of action of steroid/thyroid receptor superfamily
members. Annu Rev Biochem. 63:451–486. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mangelsdorf DJ, Thummel C, Beato M,
Herrlich P, Schütz G, Umesono K, Blumberg B, Kastner P, Mark M,
Chambon P and Evans RM: The nuclear receptor superfamily: The
second decade. Cell. 83:835–839. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
McKenna NJ and O'Malley BW: Combinatorial
control of gene expression by nuclear receptors and coregulators.
Cell. 108:465–474. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Walter P, Green S, Greene G, Krust A,
Bornert JM, Jeltsch JM, Staub A, Jensen E, Scrace G, Waterfield M,
et al: Cloning of the human estrogen receptor cDNA. Proc Natl Acad
Sci USA. 82:pp. 7889–7893. 1985; View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Green S, Walter P, Kumar V, Krust A,
Bornert JM, Argos P and Chambon P: Human estrogen receptor cDNA:
Sequence, expression and homology to v-erb-A. Nature. 320:134–139.
1986. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lin Z, Reierstad S, Huang CC and Bulun SE:
Novel estrogen receptor-alpha binding sites and estradiol target
genes identified by chromatin immunoprecipitation cloning in breast
cancer. Cancer Res. 67:5017–5024. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Finn R, Dering J, Conklin D, Kalous O,
Cohen D, Desai A, Ginther C, Atefi M, Chen I, Fowst C, et al: PD
0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially
inhibits proliferation of luminal estrogen receptor-positive human
breast cancer cell lines in vitro. Breast Cancer Res. 11:R772009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kuiper GG, Enmark E, Pelto-Huikko M,
Nilsson S and Gustafsson JA: Cloning of a novel receptor expressed
in rat prostate and ovary. Proc Natl Acad Sci USA. 93:pp.
5925–5930. 1996; View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mosselman S, Polman J and Dijkema R: ER
beta: Identification and characterization of a novel human estrogen
receptor. FEBS Lett. 392:49–53. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Leung YK, Lee MT, Lam HM, Tarapore P and
Ho SM: Estrogen receptor-beta and breast cancer: Translating
biology into clinical practice. Steroids. 77:727–737. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fox EM, Davis RJ and Shupnik MA: ERbeta in
breast cancer-onlooker, passive player, or active protector?
Steroids. 73:1039–1051. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pettersson K, Delaunay F and Gustafsson
JA: Estrogen receptor beta acts as a dominant regulator of estrogen
signaling. Oncogene. 19:4970–4978. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lazennec G: Estrogen receptor beta, a
possible tumor suppressor involved in ovarian carcinogenesis.
Cancer Lett. 231:151–157. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jensen EV, Cheng G, Palmieri C, Saji S,
Mäkelä S, van Noorden S, Wahlström T, Warner M, Coombes RC and
Gustafsson JA: Estrogen receptors and proliferation markers in
primary and recurrent breast cancer. Proc Natl Acad Sci USA. 98:pp.
15197–16202. 2001; View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Skliris GP, Leygue E, Curtis-Snell L,
Watson PH and Murphy LC: Expression of oestrogen receptor-beta in
oestrogen receptor-alpha negative human breast tumours. Br J
Cancer. 95:616–626. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Speirs V, Parkes AT, Kerin MJ, Walton DS,
Carleton PJ, Fox JN and Atkin SL: Coexpression of estrogen receptor
alpha and beta: Poor prognostic factors in human breast cancer?
Cancer Res. 59:525–528. 1999.PubMed/NCBI
|
|
21
|
Grober OM, Mutarelli M, Giurato G, Ravo M,
Cicatiello L, De Filippo MR, Ferraro L, Nassa G, Papa MF, Paris O,
et al: Global analysis of estrogen receptor beta binding to breast
cancer cell genome reveals an extensive interplay with estrogen
receptor alpha for target gene regulation. BMC Genomics. 12:362011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real time quantitative PCR and
the 2(−Delta Delta C(T)). Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yan M, Rayoo M and Takano EA; kConFab
Investigators and Fox SB, : Nuclear and cytoplasmic expressions of
ERβ1 and ERβ2 are predictive of response to therapy and alters
prognosis in familial breast cancers. Breast Cancer Res Treat.
126:395–405. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Arafah M: Correlation of hormone receptors
with Her-2 Neu protein expression and the histological grade in
invasive breast cancers in a cohort of Saudi Arabia. Turk Patoloji
Dergisi. 28:38–43. 2012.PubMed/NCBI
|
|
25
|
Isola J and Tanner M: Chromogenic in situ
hybridization in tumor pathology. Methods Mol Med. 97:133–144.
2004.PubMed/NCBI
|
|
26
|
Jonsson P, Katchy A and Williams C:
Support of a bi-faceted role of estrogen receptor β (ERβ) in
ERα-positive breast cancer cells. Endocr Relat Cancer. 21:143–160.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Huang B, Warner M and Gustafsson JÅ:
Estrogen receptors in breast carcinogenesis and endocrine therapy.
Mol Cell Endocrinol 418 Pt. 3:240–244. 2015. View Article : Google Scholar
|
|
28
|
Bièche I, Parfait B, Laurendeau I, Girault
I, Vidaud M and Lidereau R: Quantification of estrogen receptor
alpha and beta expression in sporadic breast Cancer. Oncogene.
20:8109–8115. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Miller WR: Aromatase and the breast:
Regulation and clinical aspects. Maturitas. 54:335–341. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Qui WS, Yue L, Ding AP, Sun J, Yao Y, Shen
Z and Fan LH: Co-expression of ER-beta and HER2 associated with
poorer prognosis in primary breast cancer. Clin Invest Med.
32:E250–E260. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hou YF, Yuan ST, Li HC, Wu J, Lu JS, Liu
G, Lu LJ, Shen ZZ, Ding J and Shao ZM: ERbeta exerts multiple
simulative effects on human breast carcinoma cells. Oncogene.
23:5799–5806. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Oladimeji P, Skerl R, Rusch C and
Diakonova M: Synergistic activation of ERα by estrogen and
prolactin in breast cancer cells requires tyrosyl phosphorylation
of PAK1. Cancer Res. 76:2600–2611. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Morrison G, Fu X, Shea M, Nanda S,
Giuliano M, Wang T, Klinowska T, Osborne CK, Rimawi MF and Schiff
R: Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in
circumventing endocrine resistance. Breast Cancer Res Treat.
144:263–272. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Marotti JD, Collins LC, Hu R and Tamimi
RM: Estrogen receptor-beta expression in invasive breast cancer in
relation to molecular phenotype: Results from the Nurses' Health
Study. Mod Pathol. 23:197–204. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lindberg K, Helguero LA, Omoto Y,
Gustafsson JÅ and Haldosén LA: Estrogen receptorb β represses Akt
signaling in breast cancer cells via downregulation of HER2/ HER3
and upregulation of PTEN: Implications for tamoxifen sensitivity.
Breast Cancer Res. 13:R432011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Knoop AS, Lænkholm AV, Jensen MB, Nielsen
KV, Andersen J, Nielsen D and Ejlertsen B; Danish Breast Cancer
Cooperative Group, : Estrogen receptor, Progesterone receptor, HER2
status and Ki67 index and responsiveness to adjuvant tamoxifen in
postmenopausal high-risk breast cancer patients enrolled in the
DBCG 77C trial. Eur J Cancer. 50:1412–1421. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li W, Jia M, Qin X, Hu J, Zhang X and Zhou
G: Harmful effect of ERβ on BCRP-mediated drug resistance and cell
proliferation in ERα/PR-negative breast cancer. FEBS J.
280:6128–6140. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Järvinen TA, Pelto-Huikko M, Holli K and
Isola J: Estrogen receptor beta is coexpressed with ERalpha and PR
and associated with nodal status, grade and proliferation rate in
breast cancer. Am J Pathol. 156:29–35. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Leung YK, Lee MT, Lam HM, Tarapore P and
Ho SM: Estrogen receptor-beta and breast cancer: Translating
biology into clinical practice. Steroids. 77:727–737. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li X, Huang J, Yi P, Bambara RA, Hilf R
and Muyan M: Single-chain estrogen receptors (ERs) reveal that the
ERalpha/beta heterodimer emulates functions of the ERalpha dimer in
genomic estrogen signaling pathways. Mol Cell Biol. 24:7681–7694.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
McNamara KM and Sasano H: The
intracrinology of breast cancer. J Steroid Biochem Mol Biol.
145:172–178. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Inwald EC, Klinkhammer-Schalke M,
Hofstädter F, Zeman F, Koller M, Gerstenhauer M and Ortmann O:
Ki-67 is a prognostic parameter in breast cancer patients: Results
of a large population-based cohort of a cancerregistry. Breast
Cancer Res Treat. 139:539–552. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Stope MB, Popp SL, Knabbe C and Buck MB:
Estrogen receptor alpha attenuates transforming growth factor-beta
signaling in breast cancer cells independent from agonistic and
antagonistic ligands. Breast Cancer Res Treat. 120:357–367. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yarden RI, Wilson MA and Chrysogelos SA:
Estrogen suppression of EGFR expression in breast cancer cells: A
possible mechanism to modulate growth. J Cell Biochem Suppl. 36
Suppl:S232–S246. 2001. View Article : Google Scholar
|
|
45
|
Subik K, Lee JF, Baxter L, Strzepek T,
Costello D, Crowley P, Xing L, Hung MC, Bonfiglio T, Hicks DG and
Tang P: The expression patterns of ER PR, HER2, CK5/6, EGFR, Ki-67
and AR by immunohistochemical analysis in-breast cancer cell lines.
Breast Cancer (Auckl). 4:35–41. 2010.PubMed/NCBI
|
|
46
|
Stark A, Hulka BS, Joens S, Novotny D,
Thor AD, Wold LE, Schell MJ, Melton LJ III, Liu ET and Conway K:
HER-2/neu amplification in benign breast disease and the risk of
subsequent breast cancer. J Clin Oncol. 18:267–274. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Allred DC, Clark GM, Molina R, Tandon AK,
Schnitt SJ, Gilchrist KW, Osborne CK, Tormey DC and McGuire WL:
Overexpression of HER-2/neu and its relationship with other
prognostic factors change during the progression of in situ to
invasive breast cancer. Hum Pathol. 23:974–979. 1992. View Article : Google Scholar : PubMed/NCBI
|
